Clinical Trial Update: Dose Escalation Using Hypoxia-adjusted Radiotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dose escalation with hypoxia-adjusted radiotherapy in head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Snippet

Sponsor: Rajiv Gandhi Cancer Institute & Research Center, India | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING